Which is useful for high-throughput sequencing, but is not part of sanger dna sequencing?

High-throughput sequencing technologies, also known as next-generation sequencing (NGS), are distinct from Sanger DNA sequencing in several ways. Among the various NGS technologies, Illumina Sequencing is particularly notable for its high-throughput capabilities, and it is not part of Sanger DNA sequencing.

Here’s why Illumina Sequencing stands out:

• High-Throughput Capability: Illumina Sequencing can simultaneously sequence millions of DNA fragments in a single run, making it ideal for large-scale genomic studies. This is in contrast to Sanger sequencing, which typically sequences one DNA fragment at a time.
• Sequencing-by-Synthesis (SBS): Illumina uses a sequencing-by-synthesis approach where DNA fragments are amplified and sequenced in parallel, allowing for extensive data generation. Sanger sequencing, on the other hand, uses chain-termination chemistry and is limited to lower throughput.
• Applications: Illumina Sequencing is used for whole-genome sequencing, exome sequencing, RNA sequencing, and other large-scale applications, offering a breadth of analysis that goes beyond what is typically feasible with Sanger sequencing.

Therefore, while Sanger DNA sequencing remains a valuable method for specific applications, high-throughput sequencing technologies like Illumina represent a significant advancement in sequencing capabilities, enabling the analysis of large datasets and complex genomic information.